Floatz Rating
B58/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07599423CT.gov A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07602322CT.gov LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure | — | Not Yet Recruiting | — | — | — |
NCT07594899CT.gov AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | — | Not Yet Recruiting | — | — | — |
NCT07613788CT.gov Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL | — | Not Yet Recruiting | — | — | — |
NCT07514169CT.gov The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL | — | Recruiting | — | — | — |
NCT06994169CT.gov Glofitamab in Real Life | — | Recruiting | — | — | — |
NCT07240194CT.gov The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study | — | Recruiting | — | — | — |
NCT06567366CT.gov CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors | — | Not Yet Recruiting | — | — | — |
NCT06071871CT.gov A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT06047080CT.gov An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
Show 1 more trialShow fewer
NCT04889716CT.gov CAR-T Followed by Bispecific Antibodies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Obinutuzumab (this asset) | The First Affiliated Hospital of Soochow University | P3 | B · 58 |
| Axicabtagene Ciloleucel | Zhejiang Cancer Hospital | P4 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Fludarabine | M.D. Anderson Cancer Center | P4 | BB |
| Etoposide | University of California, Davis | P2/3 | BB |
| Adriamycin | Ruijin Hospital | P3 | BB |
| Prednisone | Ruijin Hospital | P3 | BB |
| Surovatamig | AstraZeneca | P3 | B |
| Lenalidomide | Ruijin Hospital | P3 | B |
+41 more in the Large B-Cell Lymphoma cohort
Other indications for Obinutuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Richter Transformation | — | P2 | BB · 71 |
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 71 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Obinutuzumab in Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/obinutuzumab-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →